Decera Clinical Education Oncology Podcast

In this episode, Nicoletta Colombo, MD; Philipp Harter, MD, PhD; and  Alexandra Leary, MD, PhD, discuss patient cases from a live webinar on the current paradigm and long-term benefits of PARPi therapy in the treatment of ovarian cancer. Topics include:Maintenance therapy in ovarian cancerSOLO1, PRIMA, PAOLO-1 clinical dataRole of bevacizumab in treatment of ovarian cancerPresenters:Nicoletta Colombo, MDProfessor of Obstetrics and GynecologyUniversity of Milan-BicoccaEuropean Institute of OncologyMilan, ItalyPhilipp Harter, MD, PhDDeputy DirectorDepartment of Gynecology and Gynecologic OncologyEvang. Kliniken Essen-MitteEssen, GermanyAlexandra Leary, MD, PhDMedical Oncologist and Team LeaderGynecology Translational Research LabDepartment of MedicineGustave Roussy Cancer CenterParis, FranceContent based on an online CME program supported by an educational grant from AstraZeneca.New Perspectives in Ovarian Cancer: Current Paradigm and Long-term Benefits of PARPi Therapyhttps://bit.ly/3aF8Lui  Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, listen to Guy A. Young, MD, as he counsels a teenage patient with severe hemophilia A and the patient’s mother on various available treatment options and strategies for optimizing hemophilia A prophylaxis and adherence. Topics include:Overcoming challenges to adherenceChoice of standard vs extended half-life factor VIII vs emicizumabSafety and efficacy data with emicizumabPresenter:Guy A. Young, MDProfessor of PediatricsDirector, Hemostasis and Thrombosis CenterChildren’s Hospital Los AngelesUniversity of Southern California Keck School of MedicineLos Angeles, CaliforniaLink to full program:https://bit.ly/3FxrVk2 Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, George D. Demetri, MD, and Alexander Drilon, MD, discuss the biologic rationale behind testing for NTRK fusions in patients with various solid tumors, along with clinical strategies for testing. Topics include:Differences between NTRK fusions vs gene mutationsFrequency of NTRK fusions by age and tumor typeWhen to test patients for NTRK fusions and interpreting reportsMethods of testing: multiplex gene testing, next-generation sequencing of DNA vs RNA, immunohistochemistry, and liquid biopsyPresenters:George D. Demetri, MDProfessor of MedicineHarvard Medical SchoolHarvard UniversityCo-Director, Ludwig Center at HarvardSenior Vice President for Experimental TherapeuticsDirector, Sarcoma CenterDana-Farber Cancer InstituteBoston, MassachusettsAlexander Drilon, MDChief, Early Drug DevelopmentAttending, ThoracicMemorial Sloan Kettering Cancer CenterNew York, New YorkLink to full program:https://bit.ly/2YFIPfrLink to slideset based on this podcast:https://bit.ly/3amgU6w  Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Daniel W. Lin, MD; Alicia K. Morgans, MD, MPH; and David F. Penson, MD, answer audience questions from a live CCO webinar focused on current best practices and emerging strategies in androgen deprivation therapy, with questions including:How to select between GnRH agonists and antagonists for initial androgen deprivation therapy?How should androgen receptor inhibitors be incorporated into treatment paradigms for nonmetastatic castration-resistant prostate cancer and metastatic hormone-sensitive prostate cancer?How should patients with prostate cancer and bone density issues be managed?How should nonmetastatic and metastatic prostate cancer be classified in light of novel imaging modalities, and how does this affect treatment?Presenters:Daniel W. Lin, MDProfessor and Chief of Urologic OncologyDepartment of UrologyUniversity of WashingtonSeattle, WashingtonAlicia K. Morgans, MD, MPHGenitourinary Medical OncologistDana-Farber Cancer InstituteBoston, MassachusettsDavid F. Penson, MDProfessor and ChairDepartment of UrologyVanderbilt University School of MedicineNashville, Tennessee Content based on an online CME program supported by educational grants from Astellas, Bayer HealthCare Pharmaceuticals Inc., Myovant Sciences Ltd, and Pfizer, Inc.  Link to full program:https://bit.ly/3iFCis5     Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Prof. Isabelle Ray-Coquard, MD, PhD, and Bernard Doger de Spéville, MD, PhD, provide expert insights on key new data from ESMO 2021 presented for endometrial and ovarian cancers including:Data from the phase III OReO/ENGOT Ov-38 trial of olaparib rechallenge in patients with recurrent ovarian cancer previously treated with a PARP inhibitor  A subgroup analysis of KEYNOTE-775, comparing lenvatinib vs pembrolizumab vs TPC, with outcomes by tumor histology and prior lines of therapyA preplanned analysis from phase III NRG-GY004 of outcomes by HRD status for olaparib with or without cediranib vs platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancerQuality-adjusted time without symptom or toxicity from the phase III PRIMA trial of maintenance niraparib vs placebo in newly diagnosed advanced ovarian cancerPresenters:Prof. Isabelle Ray-Coquard, MD, PhDProfessor of Department of Medical OncologyClinical Science Institute of the Léon Bérard CenterLyon, FranceBernard Doger de Spéville, MD, PhDMedical OncologistSTART-Madrid, Early Phase Clinical Trials UnitHospital Fundación Jiménez DíazMadrid, SpainContent supported by an educational grant from GlaxoSmithKline.Link to full program, including a downloadable highlights slideset and ClinicalThought commentaries:https://bit.ly/3dAttwi  Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this podcast episode, Jeffrey S. Weber, MD, PhD; Allison Betof Warner, MD, PhD; and Hussein Tawbi, MD, PhD, discuss recent key data on adjuvant and neoadjuvant therapy and review the latest evidence on therapies for metastatic disease.Link to full program:https://bit.ly/3ogPjMoFollow along with the downloadable slideset:https://bit.ly/2XYNIztPresenters:  Jeffrey S. Weber, MD, PhDDeputy DirectorLaura and Isaac Perlmutter Cancer CenterNYU Langone HealthProfessor of MedicineNYU Grossman School of MedicineNew York, New YorkAllison Betof Warner, MD, PhDAssistant MemberAssistant Attending PhysicianMelanoma ServiceDivision of Solid Tumor OncologyDepartment of MedicineMemorial Sloan Kettering Cancer CenterNew York, New YorkHussein Tawbi, MD, PhDProfessorDepartment of Melanoma Medical OncologyThe University of Texas MD Anderson Cancer CenterHouston, Texas  Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Domenica Lorusso, MD, PhD, and Alexandra Leary, MD, PhD, provide expert insights on practice changing data from IGCS 2021 presented for endometrial, ovarian, and cervical cancers regarding:A subgroup analysis from phase III KEYNOTE-775 evaluating lenvatinib plus pembrolizumab efficacy in patients with advanced endometrial cancer and dMMR statusA subgroup analysis from the phase I GARNET trial─cohorts A1 and A2─in patients with advanced endometrial cancer who had received either 1 or ≥2 prior lines of therapyData from the TOTEM trial reporting survival outcomes for patients undergoing intensive vs minimalist follow-up in following treatment for endometrial cancerAn exploratory analysis from the phase III ARIEL3 trial evaluating characteristics of patients with ovarian cancer with exceptional benefit from rucaparibA post hoc analysis from the phase III NORA trial assessing efficacy of starting PARP inhibitor maintenance following either ≤4 vs >4 cycles of platinum-based chemotherapyHighly anticipated results from the phase III EMPOWER-CERVICAL 1 trial of cemiplimab vs investigator’s choice chemotherapy in women with cervical cancerPresenters:Domenica Lorusso, MD, PhDAssociate ProfessorGynecologic Oncology DepartmentClinical Research UnitFondazione Policlinico Gemelli IRCCSRome, ItalyAlexandra Leary, MD, PhDMedical Oncologist and Team Leader  Gynecology Translational Research LabDepartment of MedicineGustave Roussy Cancer CenterParis, FranceContent supported by an educational grant from GlaxoSmithKline.Link to full program, including a downloadable highlights slideset and ClinicalThought commentaries:https://bit.ly/3dAttwi Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Paul G. Richardson, MD; Nina Shah, MD; and Peter M. Voorhees, MD, answer questions from a live webinar providing their thoughts on how to select the optimal therapy for patients with relapse/refractory multiple myeloma. Topics include:Treatment after first relapsedOptimal use of CAR T-cell therapyWhen to use selinexor and belantamab mafodotinCOVID-19 vaccinations for patients with myelomaPresenters:Paul G. Richardson, MDR. J. Corman Professor of MedicineHarvard Medical SchoolClinical Program LeaderDirector of Clinical ResearchJerome Lipper Multiple Myeloma CenterDana-Farber Cancer InstituteBoston, MassachusettsNina Shah, MDProfessor of Clinical MedicineDivision of Hematology-OncologyDepartment of MedicineUniversity of California San FranciscoSan Francisco, CaliforniaPeter M. Voorhees, MDDirector, Medical Operations and Outreach ServicesDepartment of Hematology/OncologyLevine Cancer Institute, Atrium HealthCharlotte, North CarolinaContent based on an online CME program supported by educational grants from Bristol-Myers Squibb, GlaxoSmithKline, Karyopharm, Oncopeptides, and Sanofi Genzyme.Link to full program:https://bit.ly/2UIhXcL Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Dr. Joyce O’Shaughnessy, MD, leads an engaging discussion with Matthew P. Goetz, MD, and Sara Hurvitz, MD, FACP, on leveraging CDK4/6 inhibitors for the treatment of patients with metastatic HR-positive/HER2-negative breast cancer. Topics include:How the experts currently use CDK4/6 inhibitors in clinical practiceClinical implications of key studies on CDK4/6 inhibitors from ASCO 2021Strategies for counseling patients receiving CDK4/6 inhibitorsPresenters:Joyce O’Shaughnessy, MDCelebrating Women Chair in Breast Cancer ResearchDirector, Breast Cancer Research ProgramBaylor University Medical CenterTexas OncologyUS Oncology NetworkDallas, TexasMatthew P. Goetz, MDErivan K. Haub Family Professor of Cancer Research Honoring Richard F. Emslander, M.D.Professor of Oncology and PharmacologyDirector, Mayo Clinic Breast Cancer SPORECo-Leader, Women's Cancer Program, Mayo Clinic Cancer CenterCo-Chair, Mayo Breast Disease GroupDepartment of Medical OncologyMayo ClinicRochester, MinnesotaSara Hurvitz, MD, FACPProfessor of MedicineDirector, Breast Oncology ProgramDivision of Hematology-OncologyDepartment of MedicineDavid Geffen School of Medicine at UCLALos Angeles, CaliforniaLink to the full program:bit.ly/3kaJKeC Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, John L. Marshall, MD, discusses current molecular testing considerations in the treatment of patients with gastrointestinal tumors, including:Current testing approaches, including IHC and PD-L1 assays and next-generation sequencingTumor agnostic testing: MSI, TMB, and NTRK fusion testingColon cancer: RAS, BRAF, and HER2Gastric cancer: PD-L1, HER2, and morePancreatic cancer: BRCABiliary cancers: FGFR and IDH1Liquid biopsiesWhen to testPresenter:John L. Marshall, MDChief, Division of Hematology/OncologyDepartment of MedicineGeorgetown University HospitalWashington, DCContent based on an online CME program supported by educational grants from Bayer and Merck, Sharp & Dohme.Link to full program:https://bit.ly/3j4hV8J Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.